Martin Gore, PhD, FRCP, CBE from the Royal Marsden NHS Foundation, London, UK discusses the risks from immunotherapy at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. Toxicity from immunotherapy is a significant consideration as they can lead to complex consequences, in particular, the combination of immune checkpoint inhibitors and CAR T-cells. Toxicity management is therefore something that needs to become more organised and managed.